Equitable Trust Co. Has $2.62 Million Stock Position in Harrow, Inc. (NASDAQ:HROW)

Equitable Trust Co. trimmed its position in Harrow, Inc. (NASDAQ:HROW - Free Report) by 30.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,225 shares of the company's stock after selling 25,275 shares during the quarter. Equitable Trust Co. owned approximately 0.16% of Harrow worth $2,618,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Principal Financial Group Inc. acquired a new position in shares of Harrow in the third quarter worth about $329,000. Hills Bank & Trust Co acquired a new stake in shares of Harrow during the third quarter worth approximately $107,000. Rice Hall James & Associates LLC boosted its holdings in shares of Harrow by 23.1% during the third quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company's stock worth $14,157,000 after purchasing an additional 59,019 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Harrow by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,825 shares of the company's stock worth $307,000 after purchasing an additional 2,668 shares during the period. Finally, Semanteon Capital Management LP acquired a new stake in shares of Harrow during the third quarter worth approximately $686,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on HROW shares. Lake Street Capital raised their price objective on shares of Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Friday, October 4th. B. Riley reaffirmed a "buy" rating and set a $50.00 price objective on shares of Harrow in a research report on Thursday, August 29th. Finally, Craig Hallum raised their price objective on shares of Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a research report on Friday, October 4th.

Harrow Stock Up 5.2 %

HROW traded up $2.60 during midday trading on Friday, hitting $52.51. 467,677 shares of the company's stock traded hands, compared to its average volume of 517,697. The company has a market cap of $1.86 billion, a PE ratio of -55.27 and a beta of 0.76. The stock's fifty day simple moving average is $47.16 and its 200-day simple moving average is $31.29. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.60 and a quick ratio of 2.43. Harrow, Inc. has a one year low of $7.60 and a one year high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.12. Harrow had a negative net margin of 21.78% and a negative return on equity of 40.59%. The company had revenue of $48.94 million for the quarter, compared to analyst estimates of $42.78 million. As a group, equities analysts anticipate that Harrow, Inc. will post 0.09 earnings per share for the current fiscal year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.